YMAB (ymabs.com) Earnings per share growth rate in current year
Y-mAbs Therapeutics (YMAB) is retaining key researchers while simultaneously recruiting global distribution experts. Growth is driven by the success of Danyelza, the GD2-SADA platform, and new patents. However, geopolitical tensions are hindering drug exports and international trials. The YoY earnings per share (EPS) trend reflects market expectations, with the metric standing at 9.90, which helps assess earnings adaptability.
Financial and market metric breakdowns for ymabs.com (YMAB)
- stock price and consensus target price:
- business market valuation indicators:
- balance sheet equity data:
- debt and solvency information:
Total Debt to Equity Ratio Y-mAbs Therapeutics|YMAB - Long-Term Debt to Capital|Short-Term Debt to Capital Y-mAbs Therapeutics, Inc.|YMAB - Company Aggregate Debts|Debt to Book Capitalization Ratio Y-mAbs Therapeutics, Inc.|YMAB - Company Long-Term Debt|Short-Term Debt Volume Y-mAbs Therapeutics|Intermediate Coverage Ratio ymabs.com
- company profitability and valuation multiples indicators:
YMAB - Net Income|Future Net Profit Y-mAbs Therapeutics|YMAB - P/E Multiple|Future Price to Earnings Multiple Y-mAbs Therapeutics|YMAB - PEG Multiple|Company Value to EBITDA Y-mAbs Therapeutics, Inc.|YMAB - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Y-mAbs Therapeutics|YMAB - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth ymabs.com|YMAB - Earnings per share growth in current year|Net earnings per share change forecast for next year Y-mAbs Therapeutics
- company sales and revenue statistics:
Fundamental valuation:Y-mAbs Corp, YMAB
For the biotech sector, where Y-mAbs Therapeutics (YMAB) is implementing innovative radioimmunotherapy for cancer, this indicator serves as a measure of efficiency in transitioning from antibody development to monetization. By analyzing the relative annual growth of net income per share, an investor can see the percentage change in EPS compared to the previous period, allowing for an assessment of the business's actual profitability through the lens of real profit extraction.
Main competitors
Earnings per share growth rate in current year BeiGene Corp (ONC)|HALO (Halozyme Therapeutics, Inc.) - Earnings growth in current year|Earnings per share growth rate in current year revmed.com RVMD|Earnings growth in current year AAPG|Net earnings per share growth this year CG Oncology CGON|Earnings per share growth in current year UroGen URGN|Expected net earnings per share growth this year Bicara Bio (BCAX)|PSNL - Earnings per share growth in current year|ERAS - Earnings growth in current year|DCTH: Earnings growth in current year|Aura Bio (AURA) - Earnings growth in current year|CADL (Candel Therapeutics Inc.) - Earnings growth in current year|ARAY: Earnings per share increase in current year|Net earnings per share growth this year SLS (SELLAS Life Sciences Group, Inc.)|Net earnings per one share growth for the current year ACTU|Citius Oncology - Net earnings per share growth this year|Earnings per share increase in current year HURA|TARA: Net earnings per share growth this year|Earnings per share growth rate in current year Fate Pharma|Aadi Bioscience Inc (WHWK) - Earnings per share growth in current year|Earnings per share growth rate in current year TScan (TCRX)|Net earnings per share growth this year CSBR|xbiotech.com (XBIT) - Expected net earnings per share growth this year|Earnings per share growth in current year cel-sci.com (CVM)|OSTX - Earnings per share growth rate in current year|Radiopharm Theranostics - Net earnings per share growth this year|Earnings per share increase in current year ARTV|ANL - Earnings per share growth in current year|VERU - Earnings growth in current year|Tempest Therapeutics, Inc. (TPST) - Earnings per share growth in current year|XLO: Net earnings per one share growth for the current year|RENB (Renovaro Biosciences) - Earnings growth in current year|MURA: Earnings per share increase in current year|Net earnings per share growth this year KAPA (Kairos Pharma Ltd)|Net earnings per one share growth for the current year OKUR|CytoMed Therapeutics Limited - Net earnings per share growth this year|CRIS: Earnings per share growth this year|APLM - Earnings per share growth in current year|THAR - Earnings growth in current year|ADVB: Earnings growth in current year|Earnings per share growth this year GNPX|CLDI (Calidi Biotherapeutics, Inc.) - Earnings growth in current year|Earnings per share growth in current year SBFM|Earnings growth in current year XBIO|Net earnings per share growth this year Salarius Pharmaceuticals SLRX|Earnings growth in current year PPBT (Purple Biotech Ltd)|AONC - Net earnings per share growth this year|BGNE: Net earnings per share growth this year|Expected net earnings per share growth this year Checkpoint Therapeutics, Inc CKPT|ELEV: Earnings growth in current year|Earnings per share growth rate in current year iCAD Inc. (ICAD)|IKNA (Ikena) - Earnings growth in current year|Net earnings per share growth this year Notable Labs (NTBL)|Earnings growth in current year VIRX|Net earnings per share growth this year MorphoSys Corporation MOR|NAYA Biosciences - Net earnings per share growth this year|Net earnings per share change in current year Ascentage Pharma
